iCellate recently announced the appointment of Anders Nordström as new Chairman of the Board, effective January 1st 2017.

"I feel very privileged to take on this role at such exciting time for iCellate. iCellate has the potential to be a part of an important paradigm shift in cancer management, a shift which will make great difference in many years to come" says Anders.

Anders brings a wealth of experience to the iCellate Board of Directors. He has an impressive background from leading startups in the Life Science sector, by charing Genagon Therapeutics, ExScale Biospecimen Solutions, Vanadis Diagnostics, Ossdsign and being a member of the Board in Halo Genomics.